51
Since the respective approvals of Novo Nordisk’s and Eli Lilly’s blockbuster drugs a few years ago, obesity deals have become all the rage in the biopharma industry. The dealmaking here is largely dominated by big pharma companies, as they race to expand their metabolic disease pipelines amid the surging demand for next-generation weight-loss therapies. These industry giants are increasingly partnering with smaller biotechs developing…